参芪复方对GK大鼠大血管病变炎症反应及胰岛素抵抗影响的实验研究
|
摘要
目的：研究参芪复方改善2型糖尿病大血管病变炎症反应与胰岛素抵抗的作用机理,为以益气养阴、活血化瘀为治疗原则的参芪复方在临床的广泛应用提供理论依据。
方法：GK大鼠饮水中加入N-硝基-L-精氨酸甲酯(L-NAME),同时给高脂饮食35d造模。实验按GK大鼠随机血糖分为GK组18只、模型组(为阳性对照)19只、西药阿托伐他汀组(简称为西药组)18只、中药参芪复方组(简称为中药组)18只,SPF级Wistar大鼠18只作为正常Wistar对照组(简称为Wistar组),共5组。造模同时开始给药,连续35天。观察一般状况、摄食量、饮水量及体重变化。实验结束时葡萄糖氧化酶法测定空腹血糖(FPG)；酶法测定血清总胆固醇、甘油三酯(TC、TG); ELISA法测定血清C-反应蛋白(CRP)；放射免疫法测血清胰岛素(INS)含量,计算胰岛素抵抗指数(IRI)、胰岛素敏感性指数(IAI)；用Real-TimePCR测定胸主动脉ICAM-1mRNA的表达,并观察光镜下的病理形态变化。
结果：中药组动物在实验结束后FPG、TC、TG、CRP、INS的含量均较模型组有显著下降(p<0.01或p<0.05),IRI较模型组显著降低(p<0.01),IAI较模型组显著升高(p<0.01)。ICAM-1mRNA的表达也较模型组明显降低(p<0.01)。中药组动物腹主动脉内膜病变数目及程度均有明显减少(p<0.05)。
结论：参芪复方具有改善T2DM大血管病变炎症反应与胰岛素抵抗的作用。其作用可能是通过以下机制完成：①降低FPG和血清TC、TG含量；②降低血清CRP含量；③抑制主动脉ICAM-1mRNA的表达；④减轻胰岛素抵抗,升高胰岛素敏感性。
Objective To research the mechanisms of ShenQi compound recipe(SQCR)treating type 2 diabetes mellitus (T2DM) on macrovascular complications of the Inflammatory response and insulin resistance. To provid the theory bases of representing with SQCR applying Traditional Chinese Medicine in clinic.
Methods Copied T2DM model with macrovascular complications by adding Nω-nitio-L-arginine methyl ester (L-NAME) in drinking water and giving high fat diet 35 days. Divided animals into five groups according to the level of blood sugar: Goto-Kakizaki(GK), model, Atorvastatin(westernmedicine), ShenQi compound recipe(Traditional Chinese Medicine)and normal control and administrated when Copying T2DM model with macrovascular complications except normal control group. During the experiment period, observed general status and measured the values of drinking, eating, body weight. At the end, estimated Fasting blood glucose(FPG)、total cholesterol(TC)、Triglyceride(TG) with serologic enzyme method; C-reactive protein(CRP) with enzyme-linked immunosorbent assay (ELISA); insulin (INS) with radio immunoassay, count IRI、IAI; abdominal aorta intercellular adhesion molecule-1 (ICAM-1)mRNA with real time RT-PCR; abdominal aorta pathologic with light microscope.
Results FPG、IRI,content of TC、TG、CRP、INS were all decreased in SQCR group compared with model group (p<0.01 or p<0.05). IAI was increased in SQCR group compared with model group (p<0.01). The expression of abdominal aorta ICAM-1mRNA in SQCR group was also decreased remarkable compared with model group (p<0.01). SQCR could decrease the amount and the degree of infiltrated in abdominal aorta.
Conclusions SQCR has remarkable effect on macrovascular complications and Improve vascular endothelial function. The mechanisms of it may realize as follows:①Decreased FPG and the content of TC、TG;②Decreased the content of CRP;③Inhibited the expression of abdominal aorta ICAM-1mRNA;④Reduced insulin resistance and increased insulin sensitivity.
方法：GK大鼠饮水中加入N-硝基-L-精氨酸甲酯(L-NAME),同时给高脂饮食35d造模。实验按GK大鼠随机血糖分为GK组18只、模型组(为阳性对照)19只、西药阿托伐他汀组(简称为西药组)18只、中药参芪复方组(简称为中药组)18只,SPF级Wistar大鼠18只作为正常Wistar对照组(简称为Wistar组),共5组。造模同时开始给药,连续35天。观察一般状况、摄食量、饮水量及体重变化。实验结束时葡萄糖氧化酶法测定空腹血糖(FPG)；酶法测定血清总胆固醇、甘油三酯(TC、TG); ELISA法测定血清C-反应蛋白(CRP)；放射免疫法测血清胰岛素(INS)含量,计算胰岛素抵抗指数(IRI)、胰岛素敏感性指数(IAI)；用Real-TimePCR测定胸主动脉ICAM-1mRNA的表达,并观察光镜下的病理形态变化。
结果：中药组动物在实验结束后FPG、TC、TG、CRP、INS的含量均较模型组有显著下降(p<0.01或p<0.05),IRI较模型组显著降低(p<0.01),IAI较模型组显著升高(p<0.01)。ICAM-1mRNA的表达也较模型组明显降低(p<0.01)。中药组动物腹主动脉内膜病变数目及程度均有明显减少(p<0.05)。
结论：参芪复方具有改善T2DM大血管病变炎症反应与胰岛素抵抗的作用。其作用可能是通过以下机制完成：①降低FPG和血清TC、TG含量；②降低血清CRP含量；③抑制主动脉ICAM-1mRNA的表达；④减轻胰岛素抵抗,升高胰岛素敏感性。
Objective To research the mechanisms of ShenQi compound recipe(SQCR)treating type 2 diabetes mellitus (T2DM) on macrovascular complications of the Inflammatory response and insulin resistance. To provid the theory bases of representing with SQCR applying Traditional Chinese Medicine in clinic.
Methods Copied T2DM model with macrovascular complications by adding Nω-nitio-L-arginine methyl ester (L-NAME) in drinking water and giving high fat diet 35 days. Divided animals into five groups according to the level of blood sugar: Goto-Kakizaki(GK), model, Atorvastatin(westernmedicine), ShenQi compound recipe(Traditional Chinese Medicine)and normal control and administrated when Copying T2DM model with macrovascular complications except normal control group. During the experiment period, observed general status and measured the values of drinking, eating, body weight. At the end, estimated Fasting blood glucose(FPG)、total cholesterol(TC)、Triglyceride(TG) with serologic enzyme method; C-reactive protein(CRP) with enzyme-linked immunosorbent assay (ELISA); insulin (INS) with radio immunoassay, count IRI、IAI; abdominal aorta intercellular adhesion molecule-1 (ICAM-1)mRNA with real time RT-PCR; abdominal aorta pathologic with light microscope.
Results FPG、IRI,content of TC、TG、CRP、INS were all decreased in SQCR group compared with model group (p<0.01 or p<0.05). IAI was increased in SQCR group compared with model group (p<0.01). The expression of abdominal aorta ICAM-1mRNA in SQCR group was also decreased remarkable compared with model group (p<0.01). SQCR could decrease the amount and the degree of infiltrated in abdominal aorta.
Conclusions SQCR has remarkable effect on macrovascular complications and Improve vascular endothelial function. The mechanisms of it may realize as follows:①Decreased FPG and the content of TC、TG;②Decreased the content of CRP;③Inhibited the expression of abdominal aorta ICAM-1mRNA;④Reduced insulin resistance and increased insulin sensitivity.
引文
[1]Anggard EE. The endothelium:the bodys largest endocrine gland[J]. Endocrionl,1990,127(3):371-375.
[2]Sinisalo J, Paronen J, Mattila J, et al. Relation of inflammation to vascular function in patients with coronary heart disease [J] Atherosclerosis,2000,149:403-411.
[3]许樟荣,王玉珍.血脂紊乱和糖尿病大血管并发症以及胰岛素抵抗[J].中国医学科学院学报,2002,24(5)：457-461.
[4]林兰,张鸿恩,高齐健,等.降糖通脉饮胶囊治疗糖尿病血管合并症的临床研究[J].中医杂志,1992,33(8)：26.
[5]Albareda J, Rodriguez-Espinosa M, Murugo A, et al. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test[J]. Diabetologic, 2000,43:1507-1511.
[6]杜冠华等译.药理学实验指南-新药发现与药理学评价(第一版).北京.科学出版社.2001.698-712.
[7]方厚华,仇志华.糖尿病动物模型的研究进展[J].实验动物科学与管理,2001,18(2).
[8]Pciarel BF. Imparied insulin secretion and excessive hepatic glu-cose p roduction are both early events in the diabetic GK rat[J]. Am I Physiol,1996,271(4ptl):E755-E762.
[9]Tomita H, Egashira K, Kubo-moue M, et al. Inhibition of NO synthesis induces inflame-matory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels[J]. Arterioscler Thromb Vasc Biol, 1998,18(9):1456-1464.
[10]赵慧颖,下川宏明.一氧化氮合酶抑制剂(L-NAME)的药理作用与慢性血管效应[J].药学学报,1999,34(9)：646-651.
[11]Perrault LP, MaIo 0, Bidouard JP, et al. Inhibition of NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation[J].The Journal of Heart and Lung Transplantation,2003,22(4):439-442.
[12]Shiro K, Kensuke E, Chu K, et al. Increased Activity of Nuclear Factor-[kappa]B Participates in Cardiovascular Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats[J]. Circulation,2000,102 (7):806-812.
[13]Van-de-Ree, Huisman MV Strong decrease of high sensitivety O-reactive pritein with high-dose atorvastatin in patients with type 2 diabetes mellitus[J]. Atherosculerosis,2003,166(1):129-135.
[14]Bickel C, Rupprecht HJ, Blankenberg S. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion[J].Int J Cardiol,2002,82(1):25-31.
[15]Auer J, Berent R, Weber T, et al. Clinical significance of pleiotropic effects of statins:lipid reduction and beyond[J]. Curr Med Chem, 2002,9 (20):1831 -1850.
[16]张北玉,李姝娟,姜春玉,沈彦祥.阿托伐他汀对高脂血症患者凝血系统及胰岛素抵抗的影响[J].中国循环杂志,2005,20：169-171.
[17]Vinik AI, Vinik E. Prevention of the complications of diabetes [J]. Am J Manag Care,2003,9 (suppl):S63-80;quiz S81-84.
[18]中华医学会糖尿病学分会慢性并发症调查组,1991-2000年全国住院糖尿病患者慢性并发症及相关大血管病变回顾性分析[J],2002,24(5)：447-451.
[19]Sinisalo J, Paronen J, Mattila J, et al. Relation of inflammation to vascular function in patients with coronary heart disease [J]. Atherosclerosis,2000,149:403-411.
[20]Barzilay JI, Abraham L, Heckbert SR, et al. The relation of maekers of inflame mation to the development of glucose disorders in the elderly[J]. Diabetes,2001:50:2384
[21]李秀钧，邬云红.糖尿病是一种炎症性疾病?[J].中华内分泌代谢杂志,2003,19(4)：251.
[22]张红敏,参芪复方对GK大鼠低度炎症和大血管病变的影响及机理研究.[J].中国博士学位论文全文数据库,http://e34.cnki.net/kns50.
[23]Hearly B. Endothelial cells dysfunction:an emerging endocrinopathy linked to coronary disease [J]. J Am Coll Cardiol,1990,16 (2):349-356.
[24]Lebovitz HE. Insulin resistance:definition and consequences [J] ExpClin Endocrinol Diabetes,2001,109[Suppl 2]:S135-148.
[25]丁怡,王家富,段文卓,等.高糖、高胰岛素与糖尿病血管并发症的关系[J].中国慢性病预防与控制,2001,9(5)：209-210.
[26]Nishio Y, Kashiwagi A. Molecular mechanisms of endothelial dysfunction in diabetes mellitus [J]. Nippon Rinsho,2001,59(12): 2451-2459.
[27]Jaap AJ,Shore AC,Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycemia[J] Diabetologia,1997,40(2):238-243.
[28]Mather K, Anderson TJ. Verma S. Insulin actionin the vasculature: physiology and pathophysi—ology, J Vase Res,2001,38:415-422.
[29]Breuer HW. Hypertriglyceridemia:a review of clinical relevance and treatment options:focus on cerivastatin[J]. Curr Med Res Opin,2001,17 (1):60-73.
[30]李振中,尹翠梅,张玉栋,等.痰浊不化与糖尿病血管病变[J].湖北中医杂志,2004,26(6)：8.
[31]李振中,尹翠梅,等.痰浊不化与糖尿病[J].湖北中医杂志,2004,26(6)：8.
[32]李振中,尹翠梅.糖尿病血管病变探讨[J].亚洲医药,2001,12(4)：47.
[33]周国英,武雪萍,衡先培,等.Ⅱ型糖尿病气阴两虚证与胰岛素抵抗的相关性研究[J].福建中医药,2000,31(2)：8
[34]王喜瑛,郑姜卿,吕绍光.36例2型糖尿病中医不同证型的胰岛素抵抗 观察[J].福建中医学院学报,2003,13(6)：9
[35]陆灏,丁学屏,蔡淦.84例DIDDM辨证分型与IRGlucagon的关系[J]辽宁中医杂志,1998,25(9)：387
[36]唐迎雪.2型糖尿病胰岛素抵抗与中医痰瘀毒相关性研究[J].中国医药学报,2004,19(4)：237
[37]张志军.以汉方药作用原理进行新药设计的分子病理药理研究[J].国外医学中医中药分册,1998,20(4)：15.
[38]林兰.中西医结合糖尿病学[M].北京：中国医药科技出版社,1999,76-77.
[39]郭盛,何丽,刘昌玉.活血化瘀法对营养性肥胖大鼠ISI及脂肪组织中肿瘤坏死因子2a的影响[J].现代中西医结合杂志,2004,13(16)：2127-2128.
[40]尹义辉,王经武.降浊消糖饮治疗胰岛素抵抗疗效观察[J].山东中医杂志,2005,24(11)：653-654.
[41]武明东,高天舒,郑曙琴,等.化痰解瘀汤联合胰岛素治疗2型糖尿病疗效观察[J].中医药学刊,2005,23(4)729.
[42]陆灏,朱宇清,唐静芬.三黄煎对2型糖尿病大鼠胰岛素分泌等功能影响[J].辽宁中医杂志,2000,27(6)：281.
[43]张小兵,孙彬.养阴活血化痰法对2型糖尿病患者工SI和血清瘦素的影响[J].光明中医,2006,21(7)：70-71.
[44]汪何.益气养阴活血化瘀中药对治疗2型糖尿病胰岛素抵抗的影响研究[J].中医药学刊,2004,22(7)：1282.
[45]彭丽娟.健脾祛湿化痰方对2型糖尿病胰岛素抵抗的影响[J].湖北中医杂.志,2006,28(8)：29-30.
[46]李莉芬,吴玉红.健脾化痰活血法改善2型糖尿病胰岛素抵抗的临床观察[J].北京中医,2006,25(7)：395-396.
[47]谢毅强.参芪复方治疗2型糖尿病胰岛素抵抗的临床研究[J].中华实用中西医杂志,2005,18(17)：844-846.
[48]喻 红,邹先智.地黄饮子对改善糖尿病胰岛素抵抗的疗效观察[J].湖南中医药导报,2001,7(1)：19.
[49]杨明,崔志勇,王言等.人参多糖对动物正常血糖及各种实验性高血糖的影响[[J].中国中药杂志,1992,17(8)500-501.
[50]王浴生等.中药药理与应用[M],北京：人民卫生出版社,1983,983.
[51]李世辉.人参皂贰Rgl对2型糖尿病患者高凝状态作用的临床观察[J].中华实用中西医杂志,2004,4(17)：702-703.
[52]周金黄.中药药理与临床研究进展(第一册)[M].北京：中国科技出版社.1992,254-261.
[53]李皓.雷米普利黄芪治疗糖尿病肾病的疗效观察[(J].现代中西医结合杂志,2002,11(2)：301.
[54]王振钢,周金黄.中药药理与临床研究进展(第一册)[M].北京：中国科技出版社.1992,254-261.
[55]陈晓玲.黄芪对大鼠缺氧性肺动脉高压的治疗作用[J].中国中药杂志,1997.22(7)432.
[56]唐弊,张国超.黄芪注射液治疗早期糖尿病肾病蛋白尿的临床观察[J].实用医学杂志,1998,14(19)：688-689.
[57]骆和生.中药方剂的药理与临床研究进展[M].广州：华南理工大学出版社, 1991.342-344.
[58]纪耀华,张明淑.黄芪多糖的研究进展[J].长春中医学院学报,1999,15(77)：62-63.
[59]唐爱华.黄芪注射液对糖尿病血液流变学的影响[J].现代中西医结合杂志.,2001,20：256-259.
[60]舒思洁,洪爱蓉,胡宗礼等.山药对糖尿病小鼠血糖、血脂、肝糖元和心肌糖元含量的影响.咸宁医李院学报,1998：12(4)：223.
[61]舒思洁,胡宗礼等.山药对糖尿病小鼠组织丙二醛含量的影响.咸宁医学院学报,1999,13(3)：156.
[62]皮文霞,蔡宝昌,许惠琴等.山茱萸环烯醚萜总甙对糖尿病血管并发症模型大鼠血清SOD的影响[J].中药新药与临床药理,2003,14(1)：23.
[63]戴岳,杭秉茜,黄朝林.山茱萸对炎症反应的抑制作用[J].中国中药杂志,1992,17(5)：307.
[64]钱东生,罗琳,何敏,等.山茱萸乙醇提取液对2型糖尿病大鼠的治疗效应[J].南通医学院学报,2000,20(4)：337.
[65]余传隆.中药辞海[M].北京：中国医药出版社,1993,711.
[66]周慧萍.顽固性葡萄膜炎的中西医结合治疗观察[J].实用中西医结合杂志,1996,(6)：377.
[67]阴健,郭力弓.中药现代研究与临床应用[M].北京：学苑出版社,1993,274-275.
[68]李文静.丹参对体外葡萄糖与蛋白非酶结合的影响[J].上海医科大学学报,1998,25(2)：132-133.
[69]王朋,张颖,范亚明,等.水蛙、丹参对实验性动脉粥样硬化及纤溶系统的影响[J].心血管病杂志,1996,15(1)：52-55.
[70]陈少华.丹参对2型糖尿病胰岛素敏感性的影响[J].天津医科大学学报,1998，4：362-365.
[71]黄翠玲,李才,邓义斌,等.大黄对糖尿病大鼠肾组织非酶促糖基化的影响[J].中国糖尿病杂志,1996,4(2)：103.
[72]彭淑梅,王淑珍,林英.大黄对全身炎症反应综合征患儿的干预机制[J].小儿急救医学,2002,9(1)：32-33.
[73]祁素霞,潘时中.PAI-1、CRP与胰岛素抵抗及2型糖尿病的关系[J].医学综述,2007,13(3)：212.
[74]华一民.CRP与糖尿病心血管并发症的关系[J].中国误诊学杂志,2007,7(2)：243.
[75]龙敏,严钟德.C反应蛋白和糖尿病[J].国外医学·内分泌学分册，2002,22 (2)：76.
[76]文磊,李博一,宋滇平.C反应蛋白与2型糖尿病及其大血管病变的关系[J].医学综述,2006,12(1)：23.
[77]黄雌友,文格波,曹仁贤,等.葡萄糖诱导人血管内皮细胞凋亡及其对表达的影响[J].中国糖尿病杂志,2003,11(1)：37-41.
[78]Yu X, Li Y, Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits [J].Life Sci,1994,54:753-758.
[79]Barzilay JI Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the deveiopment of glucose disorders in the elderly:the Cardiovascular Health Study. Diabetes,2001,50:2384-2389.
[80]Meigs JB,0'Donnell CJ, Tofler GH, et al. Hemostatic markersof endot helial dysfunction and risk of incident type 2 diabetes[J]. Diabetes,2006,55 (2):530-537.
[81]Haidari M, Javadi E, Sadeglhi B, et al Evaluation of c-reactive Protein, a sensitivemarker of inflammaticm, as a risk factor for stablecoronary artery diseasel Clin 8iochem,2001,33:309-315.
[82]Kvasnicka J, Skrha J, Perusicova J, et al. Haemostasis, cytoadhesive molecules (sE-selectin and Sicam-1) and inflammatory markers in noninsulin dependent diabetes mellitus (NIDDM) [J]. Sb Lek, 1998,99(2):97-101.
[83]Mary S, George N, Erini D, et al. Circulating adhesionmolecules levels in type 2 diabetes mellitusand hypertension[J]. International Journal of Cardiology,2005,98:39-44.
[84]Pickup J C, Mattock M B. Actication of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellituslDiabet Med,2003,20(9):723-726.
[1]Abulebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patients with type 2 diabetes mellitus[J]. Mayo Clin Pro,2001,76: 707-712.
[2]Sica DA. Endothelial cell function:new considerations [J].Eur HeartJ,2000,21 (2):B13-B21.
[3]曾正陪.血管内皮的内分沁功能[J].中华内科杂志,1998,37(2)：77-77.
[4]Standl E,Schnell 0. A look at the heart in diabetes mellitus:from ailing to failing[J]. Diabetolia,2000,43 (12):1435-1469.
[5]Hornig B, Arakawa N, Kohler C, et al. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure [J] Circulation,1998,97(4):363-368.
[6]Skyrme R A, OBrien R C, Berry K L, et al. Vitamin E supplementation improves endothelial function in type 1 diabetes mellitus:a randomized, placebo-controlled study [J]. JACC,2000,36(1):94-102.
[7]Neri S, Signorelli SS, Torrisi B, et al. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction:a single-blind,15-day clinical trial in patients with unt-reated type 2 diabetes,subjects with impaired glucose tolerance, and healthy controls [J]. Clin Ther,2005,27(11):1764-1773.
[8]Masumoto A, Hirooka Y, Hironaga K, et al. Efect ofpravastatin on endothelial function in patients with coronary artery disease[J]. Am J Cardiol,2001,88:1291-1294.
[9]Perticone F, Ceravolo R, Mad R, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients [J]. Cardiovasc Res,1999,41(1):299-306.
[10]Anderson TJ, Elstein E, Habar H, et al. Comparative study of ACE-inhibition, angiotensin antagonism, andcaleium channel blockade on flow-mediated vasodilatation in patients with coronary disease(BANFF study) [J]. J Am Coll Cardiol, 2000,35:60-66.
[11]Taddei S, Virdis A, Ghiadon I L, et al. Effect of calcium antagonist or·beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients [J]. Hypertens,2001, 19(8):1379-1386.
[12]DengYB, Wang DW, LiCL, et al. Efects ofthe angiotenisn receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography[J]. Can J Cardiol,2002,18:389-396.
[13]林蓉.刘俊田.甘伟杰.等.川芎嗪对缺血缺糖状态下培养的血管内皮细胞VEC-304的影响[J].中国中药杂志.2004,29(5)：462-463.
[14]张冀.王韵.汪炳华.等.川芎嗪对花生四烯酸诱导血管内皮细胞凋亡的保护作用[J].中国临床康复,2003,7(30)：4066-4067.
[15]徐东波.张军平.张文志等.丹参注射液对血管内皮细胞氧化损伤保护作用的 实验[J].天津医科大学学报.2001,7(1)：21-23.
[16]赵燕.尹毅.昌晓菊等.丹参对内毒素血症早期中性粒细胞(PMN)与内皮细胞(EC)粘附作用的影响[J].四川大学学报(医学版).2004.35(3)：320-322；346.
[17]吴大正.黄芪甲甙对组胺引起血管内皮细胞单层通透性增高的作用[J].中国中医基础医学杂志.2001,7(2)：36-38.
[18]王宝华.欧阳静萍.徐淑珍等.当归抗高脂血症致内皮细胞损伤的保护作用[J].中国病理生理杂志.2000,10(16)：856.
[19]王兵,王杰军.人参皂甙Rg3对胃癌诱导血管内皮细胞(VEC)增殖的抑制作用[J].肿瘤防治杂志,2001,8(3)：234-236.
[20]绪广林,钱之玉.西红花苷对血管内皮细胞的保护作用研究[J].中草药,2002,33(5)：439-442.
[21]叶希韵,王耀发.山楂叶总黄酮对血管内皮细胞氧化损伤的保护作用[J].中国现代应用药学杂志2002,19(4)：265-268.
[22]李风文.张立石.水蛭、丹参及其复方对血瘀大鼠血管内皮细胞保护作用的研究[J].中国中药杂志.2001,26(10)：703-706.
[23]司秋菊.王鑫国.王亚利等.蜈蚣对动脉粥样硬化家兔血管内皮细胞功能的影响[J].中药药理与临床.-2002,8(6)：28-30.
[24]林桂珍.林国生.大蒜素对血管内皮细胞脂质过氧化损伤的保护作用[J].微循环学杂志.2001,11(4)：5-6.
[25]曹维娟.何靖康.姜黄素对缺氧再给氧大鼠心脏微血管内皮细胞ICAM-1表达的影响[J].中国血液流变学杂志.2002,12(4)：295-297.
[2]Sinisalo J, Paronen J, Mattila J, et al. Relation of inflammation to vascular function in patients with coronary heart disease [J] Atherosclerosis,2000,149:403-411.
[3]许樟荣,王玉珍.血脂紊乱和糖尿病大血管并发症以及胰岛素抵抗[J].中国医学科学院学报,2002,24(5)：457-461.
[4]林兰,张鸿恩,高齐健,等.降糖通脉饮胶囊治疗糖尿病血管合并症的临床研究[J].中医杂志,1992,33(8)：26.
[5]Albareda J, Rodriguez-Espinosa M, Murugo A, et al. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test[J]. Diabetologic, 2000,43:1507-1511.
[6]杜冠华等译.药理学实验指南-新药发现与药理学评价(第一版).北京.科学出版社.2001.698-712.
[7]方厚华,仇志华.糖尿病动物模型的研究进展[J].实验动物科学与管理,2001,18(2).
[8]Pciarel BF. Imparied insulin secretion and excessive hepatic glu-cose p roduction are both early events in the diabetic GK rat[J]. Am I Physiol,1996,271(4ptl):E755-E762.
[9]Tomita H, Egashira K, Kubo-moue M, et al. Inhibition of NO synthesis induces inflame-matory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels[J]. Arterioscler Thromb Vasc Biol, 1998,18(9):1456-1464.
[10]赵慧颖,下川宏明.一氧化氮合酶抑制剂(L-NAME)的药理作用与慢性血管效应[J].药学学报,1999,34(9)：646-651.
[11]Perrault LP, MaIo 0, Bidouard JP, et al. Inhibition of NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation[J].The Journal of Heart and Lung Transplantation,2003,22(4):439-442.
[12]Shiro K, Kensuke E, Chu K, et al. Increased Activity of Nuclear Factor-[kappa]B Participates in Cardiovascular Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats[J]. Circulation,2000,102 (7):806-812.
[13]Van-de-Ree, Huisman MV Strong decrease of high sensitivety O-reactive pritein with high-dose atorvastatin in patients with type 2 diabetes mellitus[J]. Atherosculerosis,2003,166(1):129-135.
[14]Bickel C, Rupprecht HJ, Blankenberg S. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion[J].Int J Cardiol,2002,82(1):25-31.
[15]Auer J, Berent R, Weber T, et al. Clinical significance of pleiotropic effects of statins:lipid reduction and beyond[J]. Curr Med Chem, 2002,9 (20):1831 -1850.
[16]张北玉,李姝娟,姜春玉,沈彦祥.阿托伐他汀对高脂血症患者凝血系统及胰岛素抵抗的影响[J].中国循环杂志,2005,20：169-171.
[17]Vinik AI, Vinik E. Prevention of the complications of diabetes [J]. Am J Manag Care,2003,9 (suppl):S63-80;quiz S81-84.
[18]中华医学会糖尿病学分会慢性并发症调查组,1991-2000年全国住院糖尿病患者慢性并发症及相关大血管病变回顾性分析[J],2002,24(5)：447-451.
[19]Sinisalo J, Paronen J, Mattila J, et al. Relation of inflammation to vascular function in patients with coronary heart disease [J]. Atherosclerosis,2000,149:403-411.
[20]Barzilay JI, Abraham L, Heckbert SR, et al. The relation of maekers of inflame mation to the development of glucose disorders in the elderly[J]. Diabetes,2001:50:2384
[21]李秀钧，邬云红.糖尿病是一种炎症性疾病?[J].中华内分泌代谢杂志,2003,19(4)：251.
[22]张红敏,参芪复方对GK大鼠低度炎症和大血管病变的影响及机理研究.[J].中国博士学位论文全文数据库,http://e34.cnki.net/kns50.
[23]Hearly B. Endothelial cells dysfunction:an emerging endocrinopathy linked to coronary disease [J]. J Am Coll Cardiol,1990,16 (2):349-356.
[24]Lebovitz HE. Insulin resistance:definition and consequences [J] ExpClin Endocrinol Diabetes,2001,109[Suppl 2]:S135-148.
[25]丁怡,王家富,段文卓,等.高糖、高胰岛素与糖尿病血管并发症的关系[J].中国慢性病预防与控制,2001,9(5)：209-210.
[26]Nishio Y, Kashiwagi A. Molecular mechanisms of endothelial dysfunction in diabetes mellitus [J]. Nippon Rinsho,2001,59(12): 2451-2459.
[27]Jaap AJ,Shore AC,Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycemia[J] Diabetologia,1997,40(2):238-243.
[28]Mather K, Anderson TJ. Verma S. Insulin actionin the vasculature: physiology and pathophysi—ology, J Vase Res,2001,38:415-422.
[29]Breuer HW. Hypertriglyceridemia:a review of clinical relevance and treatment options:focus on cerivastatin[J]. Curr Med Res Opin,2001,17 (1):60-73.
[30]李振中,尹翠梅,张玉栋,等.痰浊不化与糖尿病血管病变[J].湖北中医杂志,2004,26(6)：8.
[31]李振中,尹翠梅,等.痰浊不化与糖尿病[J].湖北中医杂志,2004,26(6)：8.
[32]李振中,尹翠梅.糖尿病血管病变探讨[J].亚洲医药,2001,12(4)：47.
[33]周国英,武雪萍,衡先培,等.Ⅱ型糖尿病气阴两虚证与胰岛素抵抗的相关性研究[J].福建中医药,2000,31(2)：8
[34]王喜瑛,郑姜卿,吕绍光.36例2型糖尿病中医不同证型的胰岛素抵抗 观察[J].福建中医学院学报,2003,13(6)：9
[35]陆灏,丁学屏,蔡淦.84例DIDDM辨证分型与IRGlucagon的关系[J]辽宁中医杂志,1998,25(9)：387
[36]唐迎雪.2型糖尿病胰岛素抵抗与中医痰瘀毒相关性研究[J].中国医药学报,2004,19(4)：237
[37]张志军.以汉方药作用原理进行新药设计的分子病理药理研究[J].国外医学中医中药分册,1998,20(4)：15.
[38]林兰.中西医结合糖尿病学[M].北京：中国医药科技出版社,1999,76-77.
[39]郭盛,何丽,刘昌玉.活血化瘀法对营养性肥胖大鼠ISI及脂肪组织中肿瘤坏死因子2a的影响[J].现代中西医结合杂志,2004,13(16)：2127-2128.
[40]尹义辉,王经武.降浊消糖饮治疗胰岛素抵抗疗效观察[J].山东中医杂志,2005,24(11)：653-654.
[41]武明东,高天舒,郑曙琴,等.化痰解瘀汤联合胰岛素治疗2型糖尿病疗效观察[J].中医药学刊,2005,23(4)729.
[42]陆灏,朱宇清,唐静芬.三黄煎对2型糖尿病大鼠胰岛素分泌等功能影响[J].辽宁中医杂志,2000,27(6)：281.
[43]张小兵,孙彬.养阴活血化痰法对2型糖尿病患者工SI和血清瘦素的影响[J].光明中医,2006,21(7)：70-71.
[44]汪何.益气养阴活血化瘀中药对治疗2型糖尿病胰岛素抵抗的影响研究[J].中医药学刊,2004,22(7)：1282.
[45]彭丽娟.健脾祛湿化痰方对2型糖尿病胰岛素抵抗的影响[J].湖北中医杂.志,2006,28(8)：29-30.
[46]李莉芬,吴玉红.健脾化痰活血法改善2型糖尿病胰岛素抵抗的临床观察[J].北京中医,2006,25(7)：395-396.
[47]谢毅强.参芪复方治疗2型糖尿病胰岛素抵抗的临床研究[J].中华实用中西医杂志,2005,18(17)：844-846.
[48]喻 红,邹先智.地黄饮子对改善糖尿病胰岛素抵抗的疗效观察[J].湖南中医药导报,2001,7(1)：19.
[49]杨明,崔志勇,王言等.人参多糖对动物正常血糖及各种实验性高血糖的影响[[J].中国中药杂志,1992,17(8)500-501.
[50]王浴生等.中药药理与应用[M],北京：人民卫生出版社,1983,983.
[51]李世辉.人参皂贰Rgl对2型糖尿病患者高凝状态作用的临床观察[J].中华实用中西医杂志,2004,4(17)：702-703.
[52]周金黄.中药药理与临床研究进展(第一册)[M].北京：中国科技出版社.1992,254-261.
[53]李皓.雷米普利黄芪治疗糖尿病肾病的疗效观察[(J].现代中西医结合杂志,2002,11(2)：301.
[54]王振钢,周金黄.中药药理与临床研究进展(第一册)[M].北京：中国科技出版社.1992,254-261.
[55]陈晓玲.黄芪对大鼠缺氧性肺动脉高压的治疗作用[J].中国中药杂志,1997.22(7)432.
[56]唐弊,张国超.黄芪注射液治疗早期糖尿病肾病蛋白尿的临床观察[J].实用医学杂志,1998,14(19)：688-689.
[57]骆和生.中药方剂的药理与临床研究进展[M].广州：华南理工大学出版社, 1991.342-344.
[58]纪耀华,张明淑.黄芪多糖的研究进展[J].长春中医学院学报,1999,15(77)：62-63.
[59]唐爱华.黄芪注射液对糖尿病血液流变学的影响[J].现代中西医结合杂志.,2001,20：256-259.
[60]舒思洁,洪爱蓉,胡宗礼等.山药对糖尿病小鼠血糖、血脂、肝糖元和心肌糖元含量的影响.咸宁医李院学报,1998：12(4)：223.
[61]舒思洁,胡宗礼等.山药对糖尿病小鼠组织丙二醛含量的影响.咸宁医学院学报,1999,13(3)：156.
[62]皮文霞,蔡宝昌,许惠琴等.山茱萸环烯醚萜总甙对糖尿病血管并发症模型大鼠血清SOD的影响[J].中药新药与临床药理,2003,14(1)：23.
[63]戴岳,杭秉茜,黄朝林.山茱萸对炎症反应的抑制作用[J].中国中药杂志,1992,17(5)：307.
[64]钱东生,罗琳,何敏,等.山茱萸乙醇提取液对2型糖尿病大鼠的治疗效应[J].南通医学院学报,2000,20(4)：337.
[65]余传隆.中药辞海[M].北京：中国医药出版社,1993,711.
[66]周慧萍.顽固性葡萄膜炎的中西医结合治疗观察[J].实用中西医结合杂志,1996,(6)：377.
[67]阴健,郭力弓.中药现代研究与临床应用[M].北京：学苑出版社,1993,274-275.
[68]李文静.丹参对体外葡萄糖与蛋白非酶结合的影响[J].上海医科大学学报,1998,25(2)：132-133.
[69]王朋,张颖,范亚明,等.水蛙、丹参对实验性动脉粥样硬化及纤溶系统的影响[J].心血管病杂志,1996,15(1)：52-55.
[70]陈少华.丹参对2型糖尿病胰岛素敏感性的影响[J].天津医科大学学报,1998，4：362-365.
[71]黄翠玲,李才,邓义斌,等.大黄对糖尿病大鼠肾组织非酶促糖基化的影响[J].中国糖尿病杂志,1996,4(2)：103.
[72]彭淑梅,王淑珍,林英.大黄对全身炎症反应综合征患儿的干预机制[J].小儿急救医学,2002,9(1)：32-33.
[73]祁素霞,潘时中.PAI-1、CRP与胰岛素抵抗及2型糖尿病的关系[J].医学综述,2007,13(3)：212.
[74]华一民.CRP与糖尿病心血管并发症的关系[J].中国误诊学杂志,2007,7(2)：243.
[75]龙敏,严钟德.C反应蛋白和糖尿病[J].国外医学·内分泌学分册，2002,22 (2)：76.
[76]文磊,李博一,宋滇平.C反应蛋白与2型糖尿病及其大血管病变的关系[J].医学综述,2006,12(1)：23.
[77]黄雌友,文格波,曹仁贤,等.葡萄糖诱导人血管内皮细胞凋亡及其对表达的影响[J].中国糖尿病杂志,2003,11(1)：37-41.
[78]Yu X, Li Y, Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits [J].Life Sci,1994,54:753-758.
[79]Barzilay JI Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the deveiopment of glucose disorders in the elderly:the Cardiovascular Health Study. Diabetes,2001,50:2384-2389.
[80]Meigs JB,0'Donnell CJ, Tofler GH, et al. Hemostatic markersof endot helial dysfunction and risk of incident type 2 diabetes[J]. Diabetes,2006,55 (2):530-537.
[81]Haidari M, Javadi E, Sadeglhi B, et al Evaluation of c-reactive Protein, a sensitivemarker of inflammaticm, as a risk factor for stablecoronary artery diseasel Clin 8iochem,2001,33:309-315.
[82]Kvasnicka J, Skrha J, Perusicova J, et al. Haemostasis, cytoadhesive molecules (sE-selectin and Sicam-1) and inflammatory markers in noninsulin dependent diabetes mellitus (NIDDM) [J]. Sb Lek, 1998,99(2):97-101.
[83]Mary S, George N, Erini D, et al. Circulating adhesionmolecules levels in type 2 diabetes mellitusand hypertension[J]. International Journal of Cardiology,2005,98:39-44.
[84]Pickup J C, Mattock M B. Actication of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellituslDiabet Med,2003,20(9):723-726.
[1]Abulebdeh HS, Hodge DO, Nguyen TT. Predictors of macrovascular disease in patients with type 2 diabetes mellitus[J]. Mayo Clin Pro,2001,76: 707-712.
[2]Sica DA. Endothelial cell function:new considerations [J].Eur HeartJ,2000,21 (2):B13-B21.
[3]曾正陪.血管内皮的内分沁功能[J].中华内科杂志,1998,37(2)：77-77.
[4]Standl E,Schnell 0. A look at the heart in diabetes mellitus:from ailing to failing[J]. Diabetolia,2000,43 (12):1435-1469.
[5]Hornig B, Arakawa N, Kohler C, et al. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure [J] Circulation,1998,97(4):363-368.
[6]Skyrme R A, OBrien R C, Berry K L, et al. Vitamin E supplementation improves endothelial function in type 1 diabetes mellitus:a randomized, placebo-controlled study [J]. JACC,2000,36(1):94-102.
[7]Neri S, Signorelli SS, Torrisi B, et al. Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction:a single-blind,15-day clinical trial in patients with unt-reated type 2 diabetes,subjects with impaired glucose tolerance, and healthy controls [J]. Clin Ther,2005,27(11):1764-1773.
[8]Masumoto A, Hirooka Y, Hironaga K, et al. Efect ofpravastatin on endothelial function in patients with coronary artery disease[J]. Am J Cardiol,2001,88:1291-1294.
[9]Perticone F, Ceravolo R, Mad R, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients [J]. Cardiovasc Res,1999,41(1):299-306.
[10]Anderson TJ, Elstein E, Habar H, et al. Comparative study of ACE-inhibition, angiotensin antagonism, andcaleium channel blockade on flow-mediated vasodilatation in patients with coronary disease(BANFF study) [J]. J Am Coll Cardiol, 2000,35:60-66.
[11]Taddei S, Virdis A, Ghiadon I L, et al. Effect of calcium antagonist or·beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients [J]. Hypertens,2001, 19(8):1379-1386.
[12]DengYB, Wang DW, LiCL, et al. Efects ofthe angiotenisn receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography[J]. Can J Cardiol,2002,18:389-396.
[13]林蓉.刘俊田.甘伟杰.等.川芎嗪对缺血缺糖状态下培养的血管内皮细胞VEC-304的影响[J].中国中药杂志.2004,29(5)：462-463.
[14]张冀.王韵.汪炳华.等.川芎嗪对花生四烯酸诱导血管内皮细胞凋亡的保护作用[J].中国临床康复,2003,7(30)：4066-4067.
[15]徐东波.张军平.张文志等.丹参注射液对血管内皮细胞氧化损伤保护作用的 实验[J].天津医科大学学报.2001,7(1)：21-23.
[16]赵燕.尹毅.昌晓菊等.丹参对内毒素血症早期中性粒细胞(PMN)与内皮细胞(EC)粘附作用的影响[J].四川大学学报(医学版).2004.35(3)：320-322；346.
[17]吴大正.黄芪甲甙对组胺引起血管内皮细胞单层通透性增高的作用[J].中国中医基础医学杂志.2001,7(2)：36-38.
[18]王宝华.欧阳静萍.徐淑珍等.当归抗高脂血症致内皮细胞损伤的保护作用[J].中国病理生理杂志.2000,10(16)：856.
[19]王兵,王杰军.人参皂甙Rg3对胃癌诱导血管内皮细胞(VEC)增殖的抑制作用[J].肿瘤防治杂志,2001,8(3)：234-236.
[20]绪广林,钱之玉.西红花苷对血管内皮细胞的保护作用研究[J].中草药,2002,33(5)：439-442.
[21]叶希韵,王耀发.山楂叶总黄酮对血管内皮细胞氧化损伤的保护作用[J].中国现代应用药学杂志2002,19(4)：265-268.
[22]李风文.张立石.水蛭、丹参及其复方对血瘀大鼠血管内皮细胞保护作用的研究[J].中国中药杂志.2001,26(10)：703-706.
[23]司秋菊.王鑫国.王亚利等.蜈蚣对动脉粥样硬化家兔血管内皮细胞功能的影响[J].中药药理与临床.-2002,8(6)：28-30.
[24]林桂珍.林国生.大蒜素对血管内皮细胞脂质过氧化损伤的保护作用[J].微循环学杂志.2001,11(4)：5-6.
[25]曹维娟.何靖康.姜黄素对缺氧再给氧大鼠心脏微血管内皮细胞ICAM-1表达的影响[J].中国血液流变学杂志.2002,12(4)：295-297.